AAZ-A-154 (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "AAZ-A-154" in English language version.

refsWebsite

Global rank English rank

9nih.gov

4^th place

6doi.org

2^nd place

3worldcat.org

5^th place

1springer.com

274^th place

309^th place

1nature.com

234^th place

397^th place

1patsnap.com

low place

1escholarship.org

1,523^rd place

976^th place

1wired.co.uk

2,053^rd place

1,340^th place

1espacenet.com

800^th place

676^th place

1acs.org

1,248^th place

1,104^th place

1web.archive.org

1^st place

1who.int

195^th place

302^nd place

acs.org (Global: 1,248^th place; English: 1,104^th place)

cen.acs.org

Cross R (2021-09-27). "Delix raises $70 million to synthesize psychedelic-inspired drugs". cen.acs.org. Archived from the original on 2021-09-27. Retrieved 2022-01-14.

doi.org (Global: 2^nd place; English: 2^nd place)

Agrawal R, Gillie D, Mungenast A, Chytil M, Engel S, Wu MC, et al. (October 2025). "Zalsupindole is a Nondissociative, Nonhallucinogenic Neuroplastogen with Therapeutic Effects Comparable to Ketamine and Psychedelics". ACS Chem Neurosci acschemneuro.5c00667. doi:10.1021/acschemneuro.5c00667. PMID 41078264.
Koenig A, van der Aa L, Pelletier N, Patat A, Viardot G, Olson D, et al. (2024). "ACNP 63rd Annual Meeting: Poster Abstracts P1-P304: P163. Phase I Results for DLX-001, a Novel Neuroplastogen Under Development for the Treatment of Major Depressive Disorder" (PDF). Neuropsychopharmacology. 49 (S1): 65–235 (157–158). doi:10.1038/s41386-024-02011-0. ISSN 0893-133X. PMC 11627186. PMID 39643633. Retrieved 31 January 2025.
Rasmussen K, Chytil M, Agrawal R, Leach P, Gillie D, Mungenast A, et al. (2024). "14. Preclinical Pharmacology of DLX-001, a Novel Non-Hallucinogenic Neuroplastogen With the Potential for Treating Neuropsychiatric Diseases". Biological Psychiatry. 95 (10). Elsevier BV: S80. doi:10.1016/j.biopsych.2024.02.192. ISSN 0006-3223.
Rasmussen K, Engel S, Chytil M, Koenig A, Meyer R, Rus M, et al. (December 2023). "ACNP 62nd Annual Meeting: Poster Abstracts P251 - P500: P361. Preclinical Pharmacology of DLX-001, a Novel Non-Hallucinogenic Neuroplastogen With the Potential for Treating Neuropsychiatric Diseases". Neuropsychopharmacology. 48 (Suppl 1): 211–354 (274–275). doi:10.1038/s41386-023-01756-4. PMC 10729596. PMID 38040810.
Dong C, Ly C, Dunlap LE, Vargas MV, Sun J, Hwang IW, et al. (May 2021). "Psychedelic-inspired drug discovery using an engineered biosensor". Cell. 184 (10): 2779–2792.e18. doi:10.1016/j.cell.2021.03.043. PMC 8122087. PMID 33915107.
Duan W, Cao D, Wang S, Cheng J (January 2024). "Serotonin 2A Receptor (5-HT2AR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants". Chem Rev. 124 (1): 124–163. doi:10.1021/acs.chemrev.3c00375. PMID 38033123.

escholarship.org (Global: 1,523^rd place; English: 976^th place)

Dunlap LE (2022). Development of Non-Hallucinogenic Psychoplastogens (Thesis). University of California, Davis. Retrieved 18 November 2024.

espacenet.com (Global: 800^th place; English: 676^th place)

worldwide.espacenet.com

WO 2020176597, Olson DE, Dunlap L, Wagner FF, "N-substituted indoles and other heterocycles for treating brain disorders", published 3 September 2020, assigned to The Regents of the University of California

nature.com (Global: 234^th place; English: 397^th place)

Koenig A, van der Aa L, Pelletier N, Patat A, Viardot G, Olson D, et al. (2024). "ACNP 63rd Annual Meeting: Poster Abstracts P1-P304: P163. Phase I Results for DLX-001, a Novel Neuroplastogen Under Development for the Treatment of Major Depressive Disorder" (PDF). Neuropsychopharmacology. 49 (S1): 65–235 (157–158). doi:10.1038/s41386-024-02011-0. ISSN 0893-133X. PMC 11627186. PMID 39643633. Retrieved 31 January 2025.

nih.gov (Global: 4^th place; English: 4^th place)

pubmed.ncbi.nlm.nih.gov

Agrawal R, Gillie D, Mungenast A, Chytil M, Engel S, Wu MC, et al. (October 2025). "Zalsupindole is a Nondissociative, Nonhallucinogenic Neuroplastogen with Therapeutic Effects Comparable to Ketamine and Psychedelics". ACS Chem Neurosci acschemneuro.5c00667. doi:10.1021/acschemneuro.5c00667. PMID 41078264.
Koenig A, van der Aa L, Pelletier N, Patat A, Viardot G, Olson D, et al. (2024). "ACNP 63rd Annual Meeting: Poster Abstracts P1-P304: P163. Phase I Results for DLX-001, a Novel Neuroplastogen Under Development for the Treatment of Major Depressive Disorder" (PDF). Neuropsychopharmacology. 49 (S1): 65–235 (157–158). doi:10.1038/s41386-024-02011-0. ISSN 0893-133X. PMC 11627186. PMID 39643633. Retrieved 31 January 2025.
Rasmussen K, Engel S, Chytil M, Koenig A, Meyer R, Rus M, et al. (December 2023). "ACNP 62nd Annual Meeting: Poster Abstracts P251 - P500: P361. Preclinical Pharmacology of DLX-001, a Novel Non-Hallucinogenic Neuroplastogen With the Potential for Treating Neuropsychiatric Diseases". Neuropsychopharmacology. 48 (Suppl 1): 211–354 (274–275). doi:10.1038/s41386-023-01756-4. PMC 10729596. PMID 38040810.
Dong C, Ly C, Dunlap LE, Vargas MV, Sun J, Hwang IW, et al. (May 2021). "Psychedelic-inspired drug discovery using an engineered biosensor". Cell. 184 (10): 2779–2792.e18. doi:10.1016/j.cell.2021.03.043. PMC 8122087. PMID 33915107.
Duan W, Cao D, Wang S, Cheng J (January 2024). "Serotonin 2A Receptor (5-HT2AR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants". Chem Rev. 124 (1): 124–163. doi:10.1021/acs.chemrev.3c00375. PMID 38033123.

ncbi.nlm.nih.gov

Koenig A, van der Aa L, Pelletier N, Patat A, Viardot G, Olson D, et al. (2024). "ACNP 63rd Annual Meeting: Poster Abstracts P1-P304: P163. Phase I Results for DLX-001, a Novel Neuroplastogen Under Development for the Treatment of Major Depressive Disorder" (PDF). Neuropsychopharmacology. 49 (S1): 65–235 (157–158). doi:10.1038/s41386-024-02011-0. ISSN 0893-133X. PMC 11627186. PMID 39643633. Retrieved 31 January 2025.
Rasmussen K, Engel S, Chytil M, Koenig A, Meyer R, Rus M, et al. (December 2023). "ACNP 62nd Annual Meeting: Poster Abstracts P251 - P500: P361. Preclinical Pharmacology of DLX-001, a Novel Non-Hallucinogenic Neuroplastogen With the Potential for Treating Neuropsychiatric Diseases". Neuropsychopharmacology. 48 (Suppl 1): 211–354 (274–275). doi:10.1038/s41386-023-01756-4. PMC 10729596. PMID 38040810.
Dong C, Ly C, Dunlap LE, Vargas MV, Sun J, Hwang IW, et al. (May 2021). "Psychedelic-inspired drug discovery using an engineered biosensor". Cell. 184 (10): 2779–2792.e18. doi:10.1016/j.cell.2021.03.043. PMC 8122087. PMID 33915107.

pubchem.ncbi.nlm.nih.gov

"(2R)-1-(5-Methoxyindol-1-yl)-N,N-dimethylpropan-2-amine". PubChem. Retrieved 27 November 2024.

patsnap.com (Global: low place; English: low place)

synapse.patsnap.com

"Delving into the Latest Updates on DLX-001 with Synapse". Synapse. 1 November 2024. Retrieved 2 November 2024.

springer.com (Global: 274^th place; English: 309^th place)

adisinsight.springer.com

"DLX 1". AdisInsight. 11 December 2023. Retrieved 2 November 2024.

web.archive.org (Global: 1^st place; English: 1^st place)

Cross R (2021-09-27). "Delix raises $70 million to synthesize psychedelic-inspired drugs". cen.acs.org. Archived from the original on 2021-09-27. Retrieved 2022-01-14.

who.int (Global: 195^th place; English: 302^nd place)

iris.who.int

https://iris.who.int/bitstream/handle/10665/380497/9789240107038-eng.pdf "zalsupindolum zalsupindole (2R)-1-(5-methoxy-1H-indol-1-yl)-N,N-dimethylpropan-2-amine antidepressant"

wired.co.uk (Global: 2,053^rd place; English: 1,340^th place)

"Can we take the high out of psychedelics?". Wired UK. ISSN 1357-0978. Retrieved 2022-07-07.

worldcat.org (Global: 5^th place; English: 5^th place)

search.worldcat.org

Koenig A, van der Aa L, Pelletier N, Patat A, Viardot G, Olson D, et al. (2024). "ACNP 63rd Annual Meeting: Poster Abstracts P1-P304: P163. Phase I Results for DLX-001, a Novel Neuroplastogen Under Development for the Treatment of Major Depressive Disorder" (PDF). Neuropsychopharmacology. 49 (S1): 65–235 (157–158). doi:10.1038/s41386-024-02011-0. ISSN 0893-133X. PMC 11627186. PMID 39643633. Retrieved 31 January 2025.
Rasmussen K, Chytil M, Agrawal R, Leach P, Gillie D, Mungenast A, et al. (2024). "14. Preclinical Pharmacology of DLX-001, a Novel Non-Hallucinogenic Neuroplastogen With the Potential for Treating Neuropsychiatric Diseases". Biological Psychiatry. 95 (10). Elsevier BV: S80. doi:10.1016/j.biopsych.2024.02.192. ISSN 0006-3223.
"Can we take the high out of psychedelics?". Wired UK. ISSN 1357-0978. Retrieved 2022-07-07.

AAZ-A-154 (English Wikipedia)

acs.org (Global: 1,248th place; English: 1,104th place)

cen.acs.org

doi.org (Global: 2nd place; English: 2nd place)

escholarship.org (Global: 1,523rd place; English: 976th place)

espacenet.com (Global: 800th place; English: 676th place)